Startups
Neomorph is a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets’. Our team is comprised of industry leading experts in protein degradation and molecular glues who have a track record of ground-breaking discoveries in the field. We are committed to leadership in advancing the science and technology of molecular glue drug discovery, while prosecuting a pipeline of projects through clinical development. Our patient-first, science-driven approach is complemented by our dedication to a supportive and collaborative work environment. Neomorph is headquartered in San Diego, California, and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute.
Overview
Location
United States, California, San Diego
Employees
51-200
Total raised
$209M
Founded date
2020
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Dec 22, 2020 | Series A round | $109M |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 29, 2024 | Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases | The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep expertise in Alzheimer... |
| Feb 27, 2024 | Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases | Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases Total potential deal value of $1.46B across multiple targets SAN DIEGO, Feb. 27, 2024 /... |
| Dec 24, 2020 | Neomorph has announced a $109M Series A to enable drug development for hard-to-treat ailments | |
| Dec 23, 2020 | Neomorph Raises $109M in Series A Financing | Neomorph, Inc., a San Diego, CA-based biotechnology company, raised $109m in Series A financing. The company intends to use the funds to further develop its platform, advance lead programs, and expand the research team. Deerfield Management... |
| Dec 23, 2020 | Neomorph Raises $109M in Series A Financing | Neomorph, Inc., a San Diego, CA-based biotechnology company, raised $109m in Series A financing. The company intends to use the funds to further develop its platform, advance lead programs, and expand the research team. Deerfield Management... |
| Dec 22, 2020 | Neomorph Finds $109M | San Diego-based Neomorph, a biotech startup focused on protein degradation, said today that it has raised $109M in a Series A funding. The funding came from Deerfield Management. The company said its targeted protein degradation technology ... |
| Dec 22, 2020 | Neomorph Secures $109M | SAN DIEGO, CA, Neomorph announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. >> Click here for more funding data on Neomorph >> To export Neomorph ... |
| Dec 22, 2020 | Neomorph Closes $109 Million Series A Financing | SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management Company established Neomorph earlier this year... |
| Neomorph | “Home - Neomorph ” |
Reviews 0
FAQ about Neomorph, Inc.
When was Neomorph, Inc. founded?
Neomorph, Inc. was founded in 2020.
How much funding has Neomorph, Inc. raised?
Neomorph, Inc. has raised $209M in total across 2 funding rounds.
What funding rounds has Neomorph, Inc. raised?
Parsers VC lists 2 funding rounds of Neomorph, Inc., among them a Series A round of $109M on Dec 22, 2020.
What has the press written about Neomorph, Inc.?
Parsers VC has collected 10 articles mentioning Neomorph, Inc., among them “Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Di...” (Oct 29, 2024) and “Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases” (Feb 27, 2024).
Is Neomorph, Inc. still active?
Yes, Neomorph, Inc. is active; its latest activity on Parsers VC dates from Apr 13, 2026.